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ABSTRACT 38 
Melanin concentrating hormone (MCH) is a hypothalamic neuropeptide with a well-39 
characterised role in energy homeostasis and emergent roles in diverse physiologic 40 
functions such as arousal, mood and reproduction.  Work to date has predominantly 41 
focused on its hypothalamic functions using animal models however little attention 42 
has been paid to its role in circulation in humans.  The aims of this study were to a) 43 
develop a radioimmunoassay for the detection of MCH in human plasma; b) 44 
establish reference ranges for circulating MCH; and c) characterize the pattern of 45 
expression of circulating MCH in humans. A sensitive and specific RIA was 46 
developed and cross-validated by RP-HPLC and MS.  The effective range was 19.5–47 
1248 pg MCH/ml.    Blood samples from 231 subjects were taken to establish a 48 
reference range of 19.5–55.4 pg/ml for fasting MCH concentrations. There were no 49 
significant differences between male and female fasting MCH concentrations 50 
however there were correlations between MCH concentrations and BMI in males and 51 
females with excess fat (p<0.001 and p=0.020) and between MCH concentrations 52 
and fat mass in females with excess fat (p=0.038). Plasma MCH concentrations rose 53 
significantly after feeding in a group of older individuals (n=50, males p=0.006, 54 
females p=0.023). There were no robust significant correlations between fasting or 55 
post-prandial MCH and resting metabolic rate, plasma glucose, insulin or leptin 56 
concentrations although there were correlations between circulating MCH and leptin 57 
concentrations in older individuals (p=0.029).  These results indicate that the role of 58 
circulating MCH may not be reflective of its regulatory hypothalamic role. 59 
Word Count: 248 60 
 61 
 62 
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 63 
INTRODUCTION 64 
Melanin concentrating hormone (MCH), is an orexigenic neuropeptide; rodent 65 
studies indicate it has multiple and diverse physiologic functions including a key role 66 
in the central control of energy metabolism.  Intracerebroventricular (ICV) 67 
administration of MCH results in hyperphagia and increased adiposity (Qu et al., 68 
1996; Gomori et al., 2002; Santollo and Eckel, 2008), whilst decreased availability of 69 
hypothalamic MCH results in hyper- or hypophagia accompanied by reduced body 70 
weight and fat mass depending on whether a pharmacological or genetic model is 71 
used (Marsh et al., 2002; Segal-Lieberman et al., 2003; Mashiko et al., 2005).   72 
Ablation of functional MCH results in increased energy expenditure via increased 73 
metabolic rate, increased locomotor activity, or both (Shimada et al., 1998; Segal-74 
Lieberman et al., 2003). MCH is expressed in the central nervous system (CNS), 75 
primarily in the rostral zona incerta/incerto-hypothalamic and the lateral hypothalamic 76 
areas (Bittencourt et al., 1992; Sita et al., 2007; Bittencourt, 2011).  Prepro-MCH 77 
mRNA and MCH have also been reported in rodent and human peripheral tissue  78 
(Hervieu and Nahon, 1995; Verlaet et al., 2002; Sandig et al., 2007).  Circulating 79 
MCH has been detected in both rodents (Bradley et al., 2000; Stricker-Krongrad et 80 
al., 2001; Sun et al., 2004) and humans (Gavrila et al., 2005; Schmidt et al., 2015) 81 
however there has been published debate concerning the validity of the detection 82 
methods used in the earlier human study (Mantzoros, 2005; Waters and Krause 83 
2005). Both central and peripherally-derived MCH are implicated in glucose 84 
homeostasis (Ludwig et al., 2001; Pereira-da-Silva et al., 2005; Bjursell et al., 2006) 85 
and there is evidence of local production of MCH in the endocrine pancreas in 86 
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rodents and humans (Pissios et al., 2007).  However the physiological role of 87 
circulating MCH remains largely unexplored at present.  88 
 89 
The overall aim of these studies was to determine whether circulating concentrations 90 
of MCH are related to body weight regulation and metabolism by developing and 91 
validating a competitive RIA for the detection of MCH in human plasma, and 92 
conducting a cross-sectional study in order to establish reference ranges for 93 
circulating MCH. Two intervention studies were also conducted to investigate 94 
whether circulating MCH concentrations were acutely responsive to food stimuli, 95 
furthermore plasma MCH concentrations in both the fasted and fed states were 96 
examined in association with circulating glucose, insulin and leptin concentrations.  97 
Additionally, associations between circulating MCH and resting metabolic rate (RMR) 98 
were investigated. 99 
 100 
MATERIALS AND METHODS 101 
MCH RIA development and validation 102 
Reverse Phase-High Performance Liquid Chromatography (RP-HPLC) and Mass 103 
Spectrometry (MS) 104 
RP-HPLC was conducted using a modified version of a previously described method 105 
(Maulon-Ferraille et al., 2002).  The optimum dilution for detection of MCH in plasma 106 
was 1:9 plasma: 0.1 N HCl (v:v).  The mixture was centrifuged at 4°C and 1000 rpm 107 
for 10 minutes and the supernatant analyzed by HPLC in a RP column (C18 108 
Phenomenex, UK) with a gradient of 20–60% (0.1% trifluoroacetic acid in HPLC 109 
water: acetonitrile) for 60 minutes at a flow rate of 0.5 ml/min. Purified MCH was 110 
serially diluted and treated similarly for comparison.  MCH was detected using UV 111 
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absorbance at 230 nm.  Protein fragments obtained by RP-HPLC were subject to MS 112 
for determination of analyte mass.  MS was performed by single quadropole mass 113 
spectrometric detector (Dionex MSQ Plus, Dionex Corp., Massachusetts, USA) and 114 
MS data analysed using Chromeleon LC/MS software (Dionex Corp., 115 
Massachusetts, USA). 116 
 117 
Blood from the same individual was collected in different vacutainers (lithium 118 
heparin, silica+gel, fluoride oxalate, EDTA and sodium citrate) to establish if there 119 
was any effect on the detection of MCH by RP-HPLC.  To determine the lability of 120 
MCH in plasma, a separate blood sample was subjected to the following conditions: 121 
room temperature 1 hour; 4°C 1 hour; room temperature overnight; 4°C overnight; -122 
20°C overnight; and -20°C before being thawed, refrozen and thawed again.  The 123 
samples were processed as described above and compared with a freshly prepared 124 
sample. 125 
 126 
RIA for MCH 127 
A double antibody RIA for MCH was developed using commercially available 128 
reagents; that is, MCH antibody (M8440: Sigma-Aldrich, UK), radiolabelled MCH 129 
(125I-MCH; NEX373010UC: PerkinElmer Inc., USA) and anti-rabbit SacCel (AA-130 
SAC1: IDS Ltd., UK).  Phosphate buffered saline with 1% bovine serum albumin 131 
(A3294: Sigma-Aldrich, UK) was used throughout.  Day 1: MCH antibody (1:30,000 132 
in 100 l) with normal rabbit serum (1:300) was added to diluted standards and 133 
unknowns and left at 4°C.  Day 2: 125I-MCH (10,000 cpm/100 l) diluted in buffer 134 
supplemented with EDTA (0.025 M) was added to each tube and left at 4°C.  Day 3: 135 
SacCel (solid phase anti-rabbit IgG coated cellulose suspension: IDS Ltd., Boldon, 136 
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UK) was added following the manufacturer’s instructions; that is, 0.1 ml SacCel were 137 
added to each tube (except total counts), left for 30 minutes at room temperature 138 
and then 1 ml deionized water was added before all tubes were centrifuged at 1000 139 
rpm and 4°C for 10 min.  The supernatant was aspirated and the resultant pellet was 140 
counted for 1 minute on a gamma counter.  Data were analysed using AssayZap 141 
(Biosoft, Cambridge, UK). 142 
 143 
To determine possible cross-reactivity, a series of dilution curves (range 0.1 pg–0.1 144 
mg) of biomolecules reported to have a competitive or agonistic relationship with 145 
MCH were treated as unknowns in the MCH assay.  Biomolecules tested were: 146 
human atrial natriuretic peptide (ANP; A1663: Sigma-Aldrich, UK) (Hervieu et al., 147 
1996); human α-MSH (H1075: Bachem, Switzerland) (Barber et al., 1987; Ludwig et 148 
al., 1998); human ACTH (H1160: Bachem, Switzerland) (Baker et al., 1985); and 149 
neuropeptide–E-I-MCH (NEI-MCH; H4714: Bachem, Switzerland) (Maulon-Ferraille 150 
et al., 2002). 151 
 152 
Comparison between RP-HPLC and RIA 153 
Plasma samples collected in EDTA tubes were diluted with either 0.1 N HCl or buffer 154 
with EDTA (1:9 dilution) with/without purified MCH and subjected to RP-HPLC.  155 
Fractions were collected at 1 minute intervals and the aliquots analysed for MCH by 156 
RIA. 157 
 158 
Circulating MCH  159 
Subjects 160 
The experiments involving human subjects were approved by the University of 161 
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Westminster’s Ethics Sub-Committee.  Each subject gave full informed consent.  162 
Fasting blood samples were taken from all subjects between 8 and 11.30 am. 163 
 164 
Cross-sectional study: Fasting venous blood samples were collected from 135 165 
females and 96 males.  Weight to the nearest 0.1 kg, height to the nearest 0.1 cm, 166 
waist and hip circumference were measured.  Total fat and lean body mass were 167 
measured by air displacement plethysmography (BodPod: Body Composition 168 
Tracking System, Version 4.1; Life Measurement Instruments, Concord, CA, USA).  169 
All venous blood samples were collected in EDTA vacutainers and plasma recovered 170 
after centrifugation.  Plasma was stored at -20˚C until MCH concentrations were 171 
determined by RIA (intra- and inter-assay CVs were 2.4% and 3.7%, respectively). 172 
 173 
Intervention studies: Two cohorts were recruited. Cohort A) 18–30 years: 21 females 174 
and 11 males. The inclusion criteria for females were: pre-menopausal (however the 175 
stage of the menstrual cycle was not recorded); non-hormonal contraceptive using; 176 
and a body mass index (BMI) of ≤24.9.  The inclusion criterion for males was BMI of 177 
≤24.9.  Cohort B) Over 40 years: a) lean individuals (11 females and 11 males) and 178 
b) those with excess body fat (13 females and 15 males).  Lean (L) was defined as 179 
<31 % body fat in females and <21 % body fat in males.  Excess body fat (E) was 180 
defined as ≥31 % body fat in females and ≥21 % body fat in males (ACSM, 1996). 181 
The inclusion criterion for both males and females was that they should be over 40 182 
years of age.  In both cohorts, those on medication(s) for chronic illness or known to 183 
cause hypo- or hyperglycaemia or affect metabolic rate and females who were 184 
pregnant, lactating or recently lactating were excluded.  185 
 186 
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Protocol. Subjects arrived after an overnight fast, anthropometric, body composition 187 
and resting metabolic rate (RMR) (Deltatrac II Metabolic Monitor, Datex 188 
Instrumentarium Corp., Helsinki, Finland) measurements were made. Fasting 189 
venous and fingerprick blood samples were obtained before subjects were fed a 190 
controlled meal of mixed macronutrient content (388 k/cal females; 510 k/cal males).  191 
Eight fingerprick samples were obtained at 15 minute intervals and 3 venous blood 192 
samples at 30, 60 and 120 minutes post meal.  Plasma was recovered from the 193 
venous blood samples and stored at -20˚C until assayed for MCH, leptin (HL-81HK, 194 
Millipore, USA; intra-assay CV: 8.3% at 4.9 ng/ml; 3.4% at 25.6 ng/ml) and insulin 195 
(DSL-1600, Diagnostic Systems Inc., USA; intra-assay CV: 8.3% at 4.8 µIU/ml; 6.4% 196 
at 54.6 µIU/ml).  All samples for each cohort were assayed for each hormone in a 197 
single assay.  The fingerprick blood samples were immediately analysed for blood 198 
glucose concentrations using the Hemocue Glucose 201+ Analyser (Hemocue AB, 199 
Sweden; intra-assay CV <1.8%).  200 
 201 
Data and Statistical Analyses 202 
RMR: The group was sub-divided based on percentage of “Standard BMR” ( Fleisch, 203 
1951). A BMR of ±10% Standard is considered normal (McArdle et al., 2001). The 204 
groups were Low (L)= ≤89.9% Standard BMR; Normal (N)=within 10% of Standard 205 
BMR; High (H)= ≥110% Standard BMR.  RMR has been used synonymously with 206 
BMR since the only condition specific to BMR that was not met was that subjects did 207 
not sleep at the facility overnight. 208 
 209 
Body composition: subjects were sub-divided into four groups based on the 210 
American College of Sports Medicine’s body fat percentage cut-off points: male lean 211 
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(ML)=body fat % <21%; male excess fat (ME)=body fat % ≥21%; female lean 212 
(FL)=body fat % <31%; female excess fat (FE)=body fat % ≥31% (ACSM, 1996).  213 
Subjects were sub-divided by body composition after data collection for the cross-214 
sectional and both intervention studies. 215 
 216 
Inter-gender differences between anthropometric characteristics and circulating 217 
hormone concentrations were established by independent samples t-tests. A one-218 
way between groups ANOVA with Tukey’s Multiple Comparison test was conducted 219 
to determine whether there was an effect of body composition on plasma MCH 220 
concentrations.   Associations between fasting plasma MCH concentrations and 221 
body composition parameters were determined by Pearson product-moment 222 
correlational analysis. Differences in pre- and post-prandial circulating hormone 223 
concentrations were assessed by paired samples t-tests. Leptin concentrations were 224 
not normally distributed and so the data were transformed using the square root 225 
before the analyses.  Comparisons between circulating hormone concentrations at 226 
the four sampling time-points were assessed by repeated measures design ANOVA.  227 
When analyzing the AUC data, only individuals with data from all four blood samples 228 
were included in the analyses and hence the lower ‘n’ values.  Data were analysed 229 
using the Statistical Package for the Social Sciences (SPSS version 16.0 for 230 
Windows; Chicago, IL, US) or Prism (Prism 5 for Mac OS X; GraphPad Software, 231 
Inc.). Statistical significance was set at p<0.05.  232 
 233 
RESULTS 234 
RIA development and validation 235 
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The gold standard method for the detection of MCH is RP-HPLC and MS hence this 236 
method was used to demonstrate that MCH is present in plasma.  Using RP-HPLC, 237 
the retention time for purified MCH was between 21 and 28 minutes (Figure 1a).  It 238 
was predicted that product ions of m/z 796 and 2 of m/z 1194 would be generated 239 
specifically for MCH and these were detected at the corresponding elution times 240 
when either purified MCH or human plasma samples were analysed by MS (Figure 241 
1b).  MCH was only detected by RP-HPLC and MS in samples collected in the 242 
lithium heparin, silica+gel and EDTA vacutainers.  No effect of storage under the 243 
conditions described could be detected when compared to freshly prepared samples 244 
measured by RP-HPLC and MS (data not shown).  Purified MCH, plasma and buffer 245 
alone were each separately fractionated by RP-HPLC and eluates collected at one 246 
minute intervals.  Immunoreactive MCH, as determined by RIA, was detected in 247 
eluates collected between 19 and 28 minutes for purified MCH and eluates collected 248 
between 18 and 24 minutes for plasma (Figure 1c). 249 
 250 
An effective range of 19.5–1248 pg MCH/ml was established and 19.5 pg/ml was 251 
taken as the level of detection.  Serial dilutions of ANP, α-MSH and ACTH failed to 252 
displace the MCH antibody demonstrating the specificity of the radioimmunoassay.  253 
Only supraphysiological concentrations of NEI-MCH showed any potential for cross-254 
reactivity with the MCH antibody (at concentrations 100x greater than MCH: data not 255 
shown).  Standard curves diluted in buffer or plasma (with unknown initial 256 
concentrations of MCH: data not shown) were parallel.  257 
 258 
Circulating MCH in humans 259 
Cross-sectional study: Demographic and anthropometric measurements of 231 260 
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subjects are presented in Table 1.  Fasting plasma MCH concentrations were 261 
detected in the range 19.5–70.4 pg/ml with the exception of one subject who had 262 
fasting MCH concentrations in excess of 150 pg/ml (this outlier was not included in 263 
Table 1 or in the statistical analyses). Within this assay 95% of the sample 264 
population would be expected to have fasting MCH concentrations between 19.5 and 265 
55.4 pg/ml.  There were no significant differences in mean fasting plasma MCH 266 
concentrations between males and females. When the sample population was 267 
grouped by gender and BMI, there were no significant differences in plasma MCH 268 
concentrations between the groups (Figure 2a) except between males with a BMI 269 
<20 compared with those with a BMI >30 (p<0.0473, ANOVA with Tukey’s Multiple 270 
Comparison test).  Fasting plasma MCH concentrations were not significantly 271 
correlated with percent fat mass, percent lean mass, height, weight or age.  There 272 
were however significant correlations between fasting plasma MCH concentrations 273 
and: a) both body fat mass weight (kg) and BMI in females with excess fat (≥31% 274 
body fat) (n=41, r=-0.326, p=0.038; n=39, r=-0.372, p=0.020, respectively); b) male 275 
BMI (n=96, r=0.230, p=0.030); and c) BMI in males with excess fat (≥21% body fat) 276 
(n=44, r=0.513, p<0.001: Figure 2b).  Note that in females the correlations were 277 
inverse whilst in males correlations were positive. 278 
 279 
Intervention studies:  Demographic, anthropometric and fasting MCH measurements 280 
are presented in Tables 2 and 3 for Cohorts A and B, respectively.  There were 281 
differences in the post-prandial plasma MCH concentrations between Cohort A 282 
(n=32) and Cohort B (n=50).  In Cohort A, there were no differences in plasma MCH 283 
concentrations at any of the four time-points (p=0.772; Figure 3). In Cohort B, 284 
plasma MCH concentrations increased after eating (females p=0.023, males 285 
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p=0.006; Figure 4).   286 
 287 
There were no differences in circulating concentrations of glucose or insulin between 288 
males and females and no effect of % body fat in either Cohort A or Cohort B.  In 289 
Cohort A, although there were no correlations with mean plasma MCH 290 
concentrations or the MCH area under the curve (AUC) and the glucose AUC, both 291 
the mean plasma MCH concentrations and the MCH AUC were correlated with the 292 
insulin AUC in all individuals (that is, both females and males) with excess fat only 293 
(that is, ≥31% body fat in females and ≥21% in males) (n=6, r=0.907, p=0.013 and 294 
n=6, r=0.932, p=0.007, respectively).  In Cohort B, there were no significant 295 
associations between mean plasma MCH concentrations or the MCH AUC and the 296 
glucose and insulin AUCs.     297 
 298 
Mean circulating leptin concentrations were greater in individuals with excess fat 299 
compared to lean individuals (Cohort A, p=0.025; Cohort B, p>0.001) and women 300 
have higher concentrations than males (Cohort A, p>0.001; Cohort B, p>0.001): 301 
Figures 3 and 4).  In both cohorts in females, circulating leptin concentrations had 302 
decreased 1 hour post-prandial (Cohort A: p=0.012; Cohort B: p=0.037).  In males, 303 
circulating leptin concentrations did not decrease significantly until 2 hours post-304 
prandial in Cohort B only (p=0.028).  In Cohort A, there were no significant 305 
correlations between plasma MCH and leptin at any time-point or the MCH and leptin 306 
AUCs. In Cohort B there were three significant correlations between plasma MCH 307 
and leptin concentrations.  There were negative correlations between plasma MCH 308 
concentrations and leptin concentrations in fasted males with excess fat (that is, 309 
≥21% body fat) (n=9, r=-0.672, p=0.047) and at 30 minutes post-prandial in females 310 
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with excess fat (that is, ≥31% body fat) (n=8, r=-0.757, p=0.030).  By contrast, there 311 
was a positive correlation between mean plasma MCH concentrations and mean 312 
plasma leptin concentrations in lean males (that is, <21% body fat) (n=11, r=0.654, 313 
p=0.029).  The MCH AUC was not significantly correlated with the leptin AUC.  314 
 315 
In both cohorts, there were no significant correlations between fasted or mean post-316 
prandial plasma MCH concentrations and RMR (for values, Tables 2 and 3) in either 317 
males or females or when categorized by adiposity. 318 
 319 
DISCUSSION 320 
A sensitive and specific RIA for the quantifiable measurement of MCH in human 321 
plasma has been successfully developed.  To confirm that MCH is detectable and 322 
measurable in human plasma cross-validation was performed by RP-HPLC and MS.  323 
A peak was detected between 21 and 28 minutes when plasma was run through the 324 
HPLC column which corresponds to the elution time of purified MCH.    Additionally, 325 
when human plasma was subject to MS, product ions of identical mass to those 326 
generated by purified MCH were observed.  Immunoreactive MCH was detected by 327 
RIA only in the eluates collected between 18 and 28 minutes of either purified MCH 328 
or human plasma.  In the RIA, the only molecule assessed showing evidence of 329 
cross-reactivity was NEI-MCH, though only at supra-physiological concentrations. 330 
Currently there is little evidence to suggest that NEI-MCH circulates therefore at 331 
physiological concentrations this assay is specific for MCH.  Furthermore, parallelism 332 
of the dilution curves of plasma to the standard curve confirmed that other plasma 333 
components have no adverse effects on the curve.  Plasma MCH retained stability 334 
under various conditions including freeze-thaw cycles and being left at room 335 
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temperature overnight.  MCH was only detected in plasma collected in lithium 336 
heparin or EDTA vacutainers or in serum tubes containing a clotting agent.  Other 337 
anti-coagulants interfered with detection.  These results indicate that collection 338 
methods for plasma MCH should be standardized, though variability in storage 339 
conditions is not detrimental. 340 
 341 
Using the RIA described herein, repeatable measures of the relative concentrations 342 
of MCH in circulation have been obtained.  The range of values obtained do vary 343 
significantly however from the two other studies published to date (Gavrila et al., 344 
2005; Schmidt et al., 2015).  The two other research groups used two different 345 
assays from the same commercial supplier and it is not known if the assays utilize 346 
the same antibody.  Neither group appeared to validate the assay they have used 347 
within their own laboratories and there is little information supplied by the company 348 
to suggest that the assays have been validated by the company itself.   Whilst it is 349 
not uncommon, as Schmidt and colleagues noted in their discussion on the 350 
differences in measurements for MCH in their studies and Gavrila and colleagues’, 351 
for there to be a wide range of baseline values reported depending on the method of 352 
assaying (for example, B-type natriuretic peptide [as reviewed by Fischer et al., 353 
2001] and oxytocin [as reviewed by Leng and Ludwig, 2016], the paucity of validation 354 
data available for the two commercial assays does preclude direct comparisons 355 
being made between their findings and those described herein.  356 
 357 
Fasting blood samples from 135 females and 96 males were obtained to establish a 358 
reference range.  Subjects were recruited from a range of ethnicities, ages and 359 
phenotypes.  The mean fasting plasma MCH concentration was 36.7±9.3 pg/ml and 360 
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95% of the population would be expected to have plasma MCH concentrations 361 
between 19.4-55.4 pg/ml.  In rodents, increased availability of hypothalamic MCH is 362 
associated with adiposity (Ludwig et al., 2001; Gomori et al., 2002) whilst decreased 363 
availability is associated with leanness (Marsh et al., 2002; Kowalski et al., 2004), 364 
therefore it was hypothesized that circulating MCH concentrations would also be 365 
aligned to fat mass in humans.  Whilst there were no associations between percent 366 
fat mass, percent lean mass, age, height or weight: there were significant 367 
correlations between circulating MCH concentrations and BMI in males and females 368 
with excess fat (that is, ≥31% body fat in females and ≥21% in males).  There was 369 
also a correlation between circulating MCH concentrations and body fat weight (kg) 370 
in females with excess fat.  These results are curious since the correlations between 371 
BMI and MCH were inverse for women and positive for men. Hence it appears there 372 
may be some gender and age related regulation which differs in the presence of 373 
adiposity.  In young males MCH may be indexed to leanness rather than adiposity 374 
since there was a positive correlation between BMI and lean body mass (kg) in the 375 
younger cohort. The two major peripheral adiposity signals; leptin and insulin are 376 
processed differently in males and females, female brains being more sensitive to 377 
leptin and male brains being more sensitive to insulin. Leptin correlates better with 378 
total body fat in females and insulin correlates better with total body fat in males 379 
(Clegg et al., 2003; Woods et al., 2003).  It could be that MCH also displays a 380 
sexually dimorphic sensitivity: whether or not fat interferes with MCH signalling either 381 
directly or indirectly via leptin resistance or some other perturbation of the system is 382 
not currently known.  383 
  384 
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There were no differences between male and female fasting circulating MCH 385 
concentrations. In this respect, our results agree with those of Gavrila and 386 
colleagues (Gavrila et al., 2005).     Age-related changes in body composition did not 387 
appear to impact on circulating MCH concentrations since there were no differences 388 
in circulating MCH concentrations between groups when all subjects in the cross-389 
sectional study were categorized by gender, age (≤30 years, 31-39 years and ≥40 390 
years) and % body fat (male lean=<21 %; male excess fat=≥ 21%; female lean=<31 391 
%; female excess fat=≥31%).  Nor was there a significant correlation between age 392 
and absolute circulating MCH concentrations.  However in the intervention studies 393 
an effect of age was observed, both in fasting MCH concentrations which were 394 
greater in the younger group compared to the older group and in the post-prandial 395 
response (compare Figures 3 and 4).  396 
 397 
In the older group circulating MCH concentrations rose significantly during the 2 hour 398 
post-prandial sampling period in males and females, and in both lean individuals and 399 
those with excess fat. In the younger group, post-prandial circulating MCH 400 
concentrations did not change significantly.  In both groups, post-ingestive circulating 401 
leptin concentrations declined significantly.  Whether or not this was related to the 402 
meal, MCH concentrations or the morning nadir of leptin requires qualification (Sinha 403 
et al., 1996).  In the lipostatic model of energy homeostasis (for review see Woods, 404 
2005), leptin inhibits the anabolic pathway through which MCH operates.  Leptin and 405 
MCH may also interact in the periphery; for example, the MCH receptor has been 406 
detected on rodent adipocytes (Bradley et al., 2000).  Whilst there is ample evidence 407 
that MCH and leptin can both inhibit and stimulate each other (Huang et al., 1999; 408 
Bradley et al., 2000; Kokkotou et al., 2001)), few studies have attempted to evaluate 409 
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the association between circulating MCH and leptin. Except for in 3 small sub-groups 410 
(within Cohort B) there were no consistent significant associations between 411 
circulating MCH and leptin concentrations: in this respect our results broadly concur 412 
with Gavrila and colleagues (2005) who found no associations with serum leptin 413 
concentrations in a younger population (17±1.7 yrs).   Leptin action is altered with 414 
aging and is characterized by increased adiposity and the development of leptin 415 
resistance: it is not known which precedes which (Carrascosa et al., 2009).  In the 416 
older individuals, it may be that the differential direction of the plasma MCH/plasma 417 
leptin relationship between those with excess fat and lean phenotypes (negative 418 
versus positive) is symptomatic of disruption between MCH and leptin signaling, in 419 
this context it is possible that MCH may be responding to some leptin resistant state. 420 
Overall there was a trend for circulating MCH and leptin concentrations to be 421 
inversely correlated which, whilst non-significant, was consistent. This would be 422 
expected if the inhibitory effect of hypothalamic leptin on hypothalamic MCH is 423 
reflected in the periphery.   424 
 425 
MCH has been shown to stimulate insulin release from beta cells in vitro and it has 426 
been suggested that MCH may be necessary for normal β-cell function (Pissios et 427 
al., 2007).  Whether or not MCH acts in a paracrine or autocrine manner within the 428 
pancreas or is released into the circulation is not known.  If MCH is active at the level 429 
of the endocrine pancreas it was hypothesised that the post-prandial insulin 430 
response might be related to the post-prandial MCH response and could be altered 431 
in the presence of insulin resistance.  Whilst there was a gender difference in the 432 
magnitude of the AUC insulin, which did not appear to be related to adiposity, our 433 
results indicate that there were no robust associations between the MCH AUC or 434 
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mean circulating MCH concentrations and the glucose or insulin AUCs.  However in 435 
the younger cohort, there was a significant positive relationship between the 436 
respective AUCs for insulin and MCH, and with the insulin AUC and mean circulating 437 
MCH concentrations but only in individuals with excess fat. Whilst in this group it 438 
would seem that the MCH and insulin response to food stimuli moves in the same 439 
direction, the small sample size of these sub-groups precludes broader application 440 
and a larger scale enquiry should be undertaken.   441 
 442 
At the outset of the intervention study with Cohort B, it was the intention to compare 443 
an older cohort with excess fat with an older leaner cohort reasoning that the more 444 
corpulent group would be more likely to have some degree of insulin resistance. 445 
However even those displaying morphological characteristics which would incline 446 
them towards insulin resistance; that is a BMI of > 30 kg/m2 and waist-hip ratio of > 447 
1.0 for men and > 0.8 for women, had fasting and 2 hour post-prandial blood glucose 448 
concentrations within the normal range (< 6.1 mmol/l fasting, < 7.8 mmol/l 2 hrs post-449 
prandial). Furthermore the individual Homeostatic Model Assessment (HOMA) 450 
scores (Matthews et al., 1985), which is a mathematical model method for detecting 451 
insulin resistance, only exceeded 2.0 in 2 individuals (data not shown). There 452 
appears to be no reference values for HOMA scores which represent insulin 453 
resistance, however scores in excess of 2.00 and 3.99 have been taken as definitive 454 
in other studies (Bakari and Onyemelukwe, 2005; Wahreneburg et al., 2005). 455 
Plasma insulin concentrations were not significantly different between those with 456 
excess fat and lean individuals at any time point and the AUCs for insulin and 457 
glucose were not different between the excess fat and lean groups of either gender. 458 
Therefore it would seem that glucose homeostasis was still normal in both the lean 459 
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group and the excess fat group, hence the hypothesis that an altered MCH response 460 
may have been observed in the presence of insulin resistance could not be further 461 
explored in the current study.  The effect of insulin resistance on circulating MCH 462 
concentrations therefore requires further investigation.   463 
 464 
Contrary to rodent studies, in humans there is little evidence to support a role for 465 
circulating MCH in energy homeostasis, therefore it was deemed important to 466 
describe associations between RMR and circulating MCH concentrations in young 467 
healthy and older individuals.  We found no evidence of a relationship between 468 
fasted or fed plasma MCH concentrations and RMR in either group.  To further 469 
explore the relationship between metabolic rate and circulating MCH regression 470 
analyses were performed.   Results indicate that factors associated with variance in 471 
RMR, that is percent fat-free mass, percent fat-mass, fat-free mass (kg) and gender, 472 
as well as RMR per se do not contribute significantly to the variance in fasted or 473 
post-prandial MCH concentrations.  These results suggest that circulating MCH 474 
cannot be considered a biomarker of resting energy expenditure in humans.   475 
 476 
In conclusion, we have demonstrated that circulating MCH can be reliably and 477 
quantifiably measured in humans by RIA.  Overall circulating MCH concentrations 478 
are not overtly reactive and no robust physiological effects of circulating MCH were 479 
observed. There does however appear to be some differential regulation in the 480 
presence of a combination of gender and adiposity which is variable depending on 481 
the population under examination. Hence, in the subjects studied here circulating 482 
MCH is not a marker of energy homeostasis, contrary to the suggestion of Gavrila 483 
and colleagues (2005).  Rather our results suggest that circulating MCH may not 484 
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have a signalling role in this context although a detailed 24 hour profile of circulating 485 
MCH should be established which would lend contextual relevance to the limited 486 
body of knowledge regarding circulating MCH in humans to date. 487 
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